RxDoctor Payments DataLook up a doctor →

Harshita Paripati, MD

Medical Oncology · Phoenix, AZNPI 1437116985

Payments from drug & device makers

$151,336in general payments, 2019–2025

Across 387 payments — averaging $391.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$74K
  • Boehringer Ingelheim$24K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$23K
  • Eli Lilly$15K
  • Novartis$4K
  • Seagen Inc.$4K
  • plus $7K from 54 others
$1,338in research payments, 2019–2025

Across 1 payment — averaging $1338.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi US Services Inc.20$74,485
Boehringer Ingelheim2$24,261
Boehringer Ingelheim Pharma GmbH & Co.kg1$22,924
Eli Lilly5$14,968
Novartis24$4,323
Seagen Inc.21$3,748
Merck26$561
AstraZeneca(2 entities)20$515
Bristol Myers Squibb22$474
Genentech USA, Inc.14$331
Pfizer22$324
Amgen16$317
E.r. Squibb & Sons, L.L.C.21$301
Takeda Pharmaceuticals U.S.A., Inc.9$230
Sanofi11$214
Regeneron Healthcare Solutions, Inc.8$198
Johnson & Johnson9$198
Gilead(2 entities)9$189
AbbVie8$166
Sanofi-aventis U.S. LLC2$163
Eisai Inc.7$148
Incyte Corporation7$147
Pharmacyclics LLC, An Abbvie Company6$141
Bayer6$136
Lilly USA, LLC7$127
Puma Biotechnology, Inc.5$119
Astellas Pharma US Inc5$101
Rigel Pharmaceuticals, Inc.3$101
Daiichi Sankyo Inc.4$99
Sobi, Inc4$94
Karyopharm Therapeutics Inc.3$91
Array Biopharma Inc5$83
Ipsen Biopharmaceuticals, Inc5$82
AMAG Pharmaceuticals, Inc.4$75
Clovis Oncology, Inc.3$64
GSK3$59
Blueprint Medicines Corporation3$58
Tersera Therapeutics LLC2$58
Global Blood Therapeutics, Inc.3$50
Pharmacosmos Therapeutics Inc.2$49
Myovant Sciences Inc.2$42
Mission Pharmacal Company1$40
Pharmaessentia USA Corporation2$40
Verastem, Inc.3$38
AVEO Pharmaceuticals, Inc.2$31
Coherus Oncology, Inc.2$30
Boston Scientific1$30
Adaptive Biotechnologies Corporation2$29
Exelixis Inc.1$28
Heron Therapeutics, Inc.2$25
Servier Pharmaceuticals LLC1$25
Genmab U.S., Inc.1$24
Morphosys, US Inc.1$24
Dendreon Pharmaceuticals LLC1$23
ADC Therapeutics America, Inc.1$22
Abbott1$22
Lexicon Pharmaceuticals, Inc.1$20
Jazz Pharmaceuticals Inc.1$19
Kyowa Kirin, Inc.1$15
Agios Pharmaceuticals, Inc.1$13

How this compares

$151,336 in reported general payments places this provider in the 65th percentile of 59 medical oncology providers in Arizona.

See all medical oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$2,211
Medicare patients
11
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →